| 1  | Article type: Original Article   |
|----|--|
| 2  | Title: Assessing the Incidence of Postoperative Diabetes in Gastric Cancer                       |
| 3  | Patients: A Comparative Study of Roux-en-Y Gastrectomy and Other Surgical                        |
| 4  | Reconstruction Techniques  |
| 5  | Onishi Tatsuki <sup>1,2*</sup>   |
| 6  | <sup>1</sup> Data Science and AI Innovation Research Promotion Center, Shiga University, Hikone, |
| 7  | Shiga, Japan   |
| 8  | <sup>2</sup> Department of Anesthesia, Juntendo University Shizuoka Hospital, Izunokuni,         |
| 9  | Shizuoka, Japan  |
| 10 |  |
| 11 |  |
| 12 | *Corresponding author:   |
| 13 | Onishi Tatsuki   |
| 14 | Email: tatsuki-onishi@biwako.shiga-u.ac.jp   |
| 15 |  |
| 16 | Running title: Postoperative Diabetes in Gastric Cancer Patients                                 |
| 17 |  |
| 18 | Acknowledgements   |

| 19 | Tatsuyoshi Ikenoue at Shiga University, Data Science and AI Innovation Research        |
|----|--|
| 20 | Promotion Center   |
| 21 |  |
| 22 | Abstract   |
| 23 | Study objective: Sleeve gastrectomy is effective in morbid obesity, and it improves    |
| 24 | glucose homeostasis. In gastric cancer patients with type 2 diabetes mellitus,         |
| 25 | gastrectomy, including total gastrectomy (TG), is beneficial for glycaemic control.    |
| 26 | However, the effects of gastrectomy and different reconstructive techniques on the     |
| 27 | incidence of postoperative diabetes in gastric cancer patients are unclear. This study |
| 28 | investigated the development of new-onset diabetes in these patients, focusing on      |
| 29 | different reconstruction methods.  |
| 30 | <b>Design</b> : A comparative study  |
| 31 | Setting: Electrical medical records  |
| 32 | Patients: This study included 715 patients without diabetes who underwent TG at        |
| 33 | Tokyo Metropolitan Bokutoh Hospital between August 2005 and March 2019.                |
| 34 | Interventions: Patients underwent reconstruction by Roux-en-Y (RY) or other surgical   |
| 35 | techniques (OT), with diabetes onset determined by HbA1c levels or medical records.    |
| 36 | Measurements: Analyses included two-sample t-tests, chi-squared tests, and the         |

37 Kaplan-Meier method with log-rank tests to compare the onset curves between the two 38 groups. Main Results: Stratified data analysis compared the RY and OT reconstruction methods. 39 Log-rank test results (P=0.0217) indicated a statistically significant difference in the 40 41 incidence of new-onset diabetes between RY and OT groups in gastric cancer patients. 42 Conclusion: This first-of-its-kind study provides insight into how different methods of gastric reconstruction affect postoperative diabetes. The results suggest significant 43 44 differences in new-onset diabetes mellitus after surgery based on the reconstruction 45 method. This research highlights the need for careful surgical planning to consider 46 potential postoperative diabetes, particularly in patients with a family history of diabetes 47 mellitus. Future studies should investigate the role of gut microbiota and other 48 reconstructive techniques, such as laparoscopic jejunal interposition, in developing 49 postoperative diabetes. 50 51 **Keywords:** Diabetes mellitus, gastrectomy, gastric cancer surgery, glucose metabolism, 52 postoperative diabetes onset, surgery outcomes 53 54 1. Introduction

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Gastrectomy, particularly sleeve gastrectomy (SG), has been shown to be an effective surgical option for morbid obesity due to its low complication rates and significant weight loss results [1–5]. SG results in alteration of the appetite through the regulation of gut hormones, resulting in decreased hunger and increased satiety [6]. SG also improves glucose homeostasis through resulting changes in gut hormone levels [7]. Specifically, laparoscopic SG results in significant improvement in glucose metabolism in morbidly obese patients and has been found to stop the development of diabetes at a high rate [8]. SG has been shown to improve blood glucose independently of weight loss by restoring hepatic insulin sensitivity [9]. However, the effects of gastrectomy on non-obese patients with type 2 diabetes are less clear, with some studies suggesting that gastrectomy may improve diabetic status [10]. In patients with gastric cancer diagnosed with type 2 diabetes mellitus (T2DM), gastrectomy has been found to have a positive impact on their glycemic control. Improvements in glycemic control, or even diabetes remission, have been reported after gastrectomy [10–15]. The extent of the gastrectomy, duration of diabetes, and method of reconstruction have been identified as important factors influencing the improvements in glycemic control [10–14]. Although the mechanisms underlying these effects are not fully understood, oncometabolic surgeries, including gastrectomy, have been suggested

as a potential treatment for T2DM in patients with gastric cancer [16].

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Studies have shown that total gastrectomy (TG) is associated with improved glucose metabolism in patients with gastric cancer, resulting in a lower rate of newly diagnosed diabetes after surgery [22]. However, the effects of gastrectomy on glucose metabolism in diabetic and non-diabetic patients have been inconsistent, with some studies reporting significant reductions in fasting blood glucose levels after gastrectomy [23]. Furthermore, SG has been associated with significant reductions in HbA1c levels in non-diabetic patients, suggesting its possible role in the prevention of type 2 diabetes [24]. In terms of reconstruction after partial gastrectomy in patients with gastric cancer, both Roux-en-Y and Billroth II reconstructions have been considered acceptable options [17]. Roux-en-Y reconstruction is often preferred for gastric cancer patients, given that this procedure can lead to decreased reflux gastritis and esophagitis, decreased probability of cancer recurrence, and decreased incidence of surgical complications [18]. Roux-en-Y reconstruction has also been found to be as effective as other methods with respect to nutritional status and postoperative outcomes [19]. In comparison to Billroth II reconstruction, Roux-en-Y has been shown to have similar postoperative complications and better long-term outcomes [20]. Furthermore,

Roux-en-Y reconstruction without cutting has been the preferred method in cases of gastritis, bile reflux, and gastric residuals [21].

Various studies have examined the impact of different reconstructive procedures on postoperative complications in gastric cancer patients. It has been found that long-limb Roux-en-Y bypass reconstruction could lead to improved glycemic control [25], and it has been observed that pre-existing diabetes is associated with postoperative complications [10, 26]. Several studies further support the benefits of Roux-en-Y reconstruction, with some indicating it to be more effective than Billroth II reconstruction [27, 28]. Additionally, significant improvements in diabetes control have been associated with Roux-en-Y reconstruction [25, 28].

Given these, the aim of this research was to investigate the incidence of new-onset diabetes in patients with gastric cancer after surgery and how this incidence varies with different types of surgical reconstruction, namely, the Roux-en-Y procedure and other alternative reconstruction techniques. While studies have investigated how surgical treatment for gastric cancer affects existing diabetes [25, 28], none have investigated the development of new-onset diabetes in patients without diabetes; to the best of our knowledge, this is the very first study to do so. Findings from this study could contribute valuable insights into the postoperative outcomes associated with

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

different gastric reconstruction techniques. Such insights are vital for guiding clinical decisions and optimizing patient care, particularly in the context of mitigating the risk of developing diabetes after gastric surgery. Moreover, findings from this study are expected to have significant implications for both clinical practice and future research in the field of gastric surgery and diabetes prevention. 2. Materials and Methods 2.1 Study participants A total of 715 patients who underwent TG as the definitive procedure and as a standby procedure at the Tokyo Metropolitan Bokutoh Hospital between August 2005 and March 2019 and were not diagnosed with diabetes at the time of surgery were included in the study (Table 1). The study was approved by the institution's ethics committee (30-110) and conducted in accordance with the Declaration of Helsinki. 2.2 Methods Whether the patients would undergo reconstruction through Roux-en-Y (RY) or other surgical techniques (OT) was chosen based on previous studies, and the patients

were grouped accordingly. The definite onset of diabetes in the patients was considered

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

based on the previous electronic medical records or when their HbA1c value was greater than 6.5 based on laboratory testing. The competing outcome was death. After a meticulous data curation process using Python 3.10 that corrects for missing values, manages outliers, and ensures appropriate data types, we obtained a data set that was optimized for analysis and free of common data inconsistencies. Furthermore, basic statistical measures such as the mean, median, and standard deviation were computed using Python 3.10. Two sample t-test and Chi-squared test for variables in characteristics were used to assess the difference in demographics of the two groups using Python 3.10. In addition, the Kaplan–Meier method was employed to estimate the onset function from the time-event data present and was augmented with log-rank tests to help compare the onset curves between the RY and OT groups using Python 3.10. 3. Results The characteristics of the patients included in the study at the time of the surgery are shown in Table 1. In the present study, following rigorous data pre-processing, a Kaplan–Meier onset curve was constructed to estimate the function delineating the interval between the

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

total gastrectomy and the subsequent emergence of new-onset diabetes postoperatively (Fig. 1). This nonparametric approach provides a survival function, articulated as a step function, which quantifies the probability of patients remaining free from diabetes up to a specific time point following surgery. The analytical framework was further refined by stratifying the data to draw comparisons between the two types of reconstruction methods applied, the RY and OT. This stratification was imperative for a granular comparison of the incidence rates of postoperative diabetes associated with these distinct reconstructive procedures. Kaplan–Meier curves were employed for each stratified group, offering a visual representation of the temporal pattern of diabetes onset post-surgery corresponding to each surgical technique. The rate of diabetes onset was inferred from the slope of these curves, with a steeper decline indicating a higher incidence within the respective group. To statistically ascertain the significance of the disparities observed in the incidence curves between the groups, a log-rank test was conducted. The resultant P-value from this log-rank test was found to be 0.0217, which denotes a statistically significant difference in the incidence of new-onset diabetes post-surgery between those who underwent RY and those subjected to OT in patients with gastric cancer. These findings indicate a difference in the incidence of postoperative diabetes based on the

type of gastric reconstruction method employed.

## 4. Discussion

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

This study is the first to provide insights into how different methods of gastric reconstruction might affect the risk of developing postoperative diabetes. This analysis is important for understanding the temporal dynamics of diabetes development after gastric surgery and has significant implications for surgical planning and patient management to prevent postoperative diabetes. A thorough approach to data pre-processing and the use of robust statistical methods will ensure the reliability and validity of these findings in the wider context of gastric surgery and diabetes research. Although the results of this study show that RY is associated with a higher incidence of new-onset postoperative diabetes compared with OT, these data could be improved by comparison with a population that has not undergone total gastrectomy as a control. Nevertheless, the finding that new-onset diabetes mellitus after surgery differs according to the method of gastric cancer reconstruction should be an important consideration in surgical selection, especially in cases with a strong family history of diabetes mellitus.

Surgery for gastric cancer, particularly gastrectomy, has been shown to

significantly alter the gut microbiota, leading to dysbiosis characterized by changes in bacterial content and gene function [31, 32]. This dysbiosis is associated with intestinal inflammation, overgrowth of small intestinal bacteria and an increased risk of colorectal cancer [32]. Specific changes in the gut microbiota after surgery include increased species richness, decreased butyrate-producing bacteria, and enrichment of certain symbiotic bacteria [33]. The abundance of specific gut bacterial genera has been found to correlate with the population of peripheral immune cells [33-35].

This study did not include an assessment of other determinants that could potentially influence the development of diabetes mellitus, including lifestyle choices and genetic predisposition. It is plausible that there may be a difference in the intrinsic characteristics of diabetes mellitus in patients who present with diabetic symptoms prior to undergoing surgery for gastric cancer, as opposed to those in whom the onset of gastric malignancy precedes the development of diabetes mellitus. Such considerations were beyond the scope of analysis within the parameters of the current study.

Similarly, laparoscopic jejunal interposition (LJIP) reconstruction, a surgical technique used to treat gastric cancer in which a pouch is created in the jejunum and used to reconstruct the upper gastrointestinal tract, may be appropriate for patients with impaired glucose tolerance [36]. Studies have shown that LJIP reconstruction leads to

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

better postoperative outcomes, including improved quality of life and nutritional status, compared with other reconstruction methods, such as double tract reconstruction [36-39]. The procedure has also been successfully performed laparoscopically with promising results in terms of operative time, blood loss and postoperative recovery [40, 41]. In this study, LJIP reconstruction was not performed at the institution, and it was not possible to study the gut microbiota. With access to a suitable dataset, we would like to investigate the association between gut microbiota and the development of new-onset diabetes after surgery further based on different reconstructive methods, including LJIP reconstruction. Acknowledgements Tatsuyoshi Ikenoue at Shiga University, Data Science and AI Innovation Research Promotion Center for proof reading, Yoshika Onishi at Wellbeing Keiei LLC for proof reading **Funding** No funding

Data availability statement 217 218 Data is available upon request to the corresponding author. Codes have been uploaded 219 here https://github.com/bougtoir/gastric\_dm 220 221 **Conflict of Interests** The authors declare no conflict of interest. 222 223 **Author contributions** 224 O.T.: conceptualization, writing - original draft, data curation, visualization, and final 225 approval of the manuscript. 226 227 228 References 229 1. Gumbs AA, Gagner M, Dakin G, Pomp A. Sleeve gastrectomy for morbid obesity. Obes Surg. 2007;17(7):962–9. doi:10.1007/s11695-007-9151-x 230 231 2. Huang R, Ding X, Fu H, Cai Q. Potential mechanisms of sleeve gastrectomy for 232 reducing weight and improving metabolism in patients with obesity. Surg Obes 233 Relat Dis. 2019;15(10):1861-71. doi:10.1016/j.soard.2019.06.022

- 3. Butte JM, Devaud N, Jarufe NP, Boza C, Pérez G, Torres J, Pérez-Ayuso RM,
- Arrese M, Martínez J. Sleeve gastrectomy as treatment for severe obesity after
- orthotopic liver transplantation. Obes Surg. 2007;17(11):1517-9.
- 237 doi:10.1007/s11695-008-9432-z.
- 4. Rawlins L, Rawlins MP, Brown CC, Schumacher DL. Sleeve gastrectomy: 5-year
- outcomes of a single institution. Surg Obes Relat Dis. 2013;9(1):21-5.
- 240 doi:10.1016/j.soard.2012.08.014
- 5. Armstrong J, O'Malley SP. Outcomes of sleeve gastrectomy for morbid obesity: a
- safe and effective procedure?. Int J Surg. 2010;8(1):69-71.
- 243 doi:10.1016/j.ijsu.2009.11.004
- 6. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and
- bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014;2(2):152-64.
- 246 doi:10.1016/S2213-8587(13)70218-3.
- 7. Papamargaritis D, et al. Mechanisms of weight loss after sleeve gastrectomy and
- adjustable gastric banding: Malabsorption versus restriction. Surg Obes Relat Dis.
- 249 2012. doi:10.1016/j.soard.2011.09.033
- 8. Natoudi M, et al. Laparoscopic sleeve gastrectomy for morbid obesity: 5-year
- results. Surg Obes Relat Dis. 2013. doi:10.1016/j.soard.2012.09.006

252 9. Abu-Gazala S, Horwitz E, Ben-Haroush Schyr R, Bardugo A, Israeli H, Hija A, 253 Schug J, Shin S, Dor Y, Kaestner KH, Ben-Zvi D. Sleeve Gastrectomy Improves Glycemia Independent of Weight Loss by Restoring Hepatic Insulin Sensitivity. 254 Diabetes. 2018;67(6):1079-85. doi:10.2337/db17-1028 255 256 10. Kang KC, et al. Influence of gastric bypass surgery on resting energy expenditure in 257 morbidly obese patients. Surg Obes Relat Dis. 2012. doi:10.1016/j.soard.2011.06.019 258 259 11. Rahakrishnan L, Haridas TV. The effect on glycemic status in type 2 diabetes 260 mellitus after gastric cancer surgery. Int Surg J. 2021. 261 doi:10.18203/2349-2902.isj20205880 262 12. An JY, Kim YM, Yun MA, Jeon BH, Noh SH. Improvement of type 2 diabetes 263 mellitus after gastric cancer surgery: short-term outcome analysis after gastrectomy. 264 World J Gastroenterol. 2013;19(48):9410–7. doi:10.3748/wjg.v19.i48.9410 265 13. Lee YK, Lee EK, Lee YJ, et al. Metabolic Effects of Gastrectomy and Duodenal 266 Bypass in Early Gastric Cancer Patients with T2DM: A Prospective Single-Center 267 Cohort Study. J Clin Med. 2021;10(17):4008. doi:10.3390/jcm10174008 268 14. Guner A, Cho M, Son T, Kim HI, Noh SH, Hyung WJ. Improved glycemic control 269 with proximal intestinal bypass and weight loss following gastrectomy in non-obese

| 270 | diabetic gastric cancer patients. Oncotarget. 2017;8(61):104605-14.                   |
|-----|---|
| 271 | doi:10.18632/oncotarget.22262   |
| 272 | 15. Wei FX, Zhang HH, Wang HL, et al. Impact of sub-gastrectomy on glucose            |
| 273 | regulation in gastric cancer patients with T2DM: a follow-up study. Int J Diabetes    |
| 274 | Dev Ctries. 2016;36(1):89-94. doi:10.1007/s13410-015-0437-6                           |
| 275 | 16. Cheng YX, Peng D, Tao W, Zhang W. Effect of oncometabolic surgery on gastric      |
| 276 | cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond. World    |
| 277 | J Gastrointest Oncol. 2021;13(9):1157–63. doi:10.4251/wjgo.v13.i9.1157                |
| 278 | 17. Ho TW, Wu JM, Yang CY, Lai HS, Lai F, Tien YW. Total gastrectomy improves         |
| 279 | glucose metabolism on gastric cancer patients: a nationwide population-based study.   |
| 280 | Surg Obes Relat Dis. 2015;12(3):635-41. doi:10.1016/j.soard.2015.11.024               |
| 281 | 18. Jin HY, Park TS, Lee KA, Baek YH. The influence of total or sub-total gastrectomy |
| 282 | on glucose control in diabetic and non-diabetic patients. Acta Endocrinol.            |
| 283 | 2016;12(4):423–30. doi:10.4183/aeb.2016.423   |
| 284 | 19. Özdaş S, Olt S, Şirik M. The role of sleeve gastrectomy on preventing type 2      |
| 285 | diabetes mellitus. Open Access Maced J Med Sci. 2017;5(3):316–8.                      |
| 286 | doi:10.3889/oamjms.2017.074   |

20. Tran TB, Worhunsky DJ, Squires MH, et al. To Roux or not to Roux: a comparison 287 between Roux-en-Y and Billroth II reconstruction following partial gastrectomy for 288 gastric cancer. Gastric Cancer. 2016;19(3):994-1001. 289 doi:10.1007/s10120-015-0547-3 290 291 21. Hoya Y, Mitsumori N, Yanaga K. The advantages and disadvantages of a Roux-en-Y 292 reconstruction after a distal gastrectomy for gastric cancer. Surg Today. 2009;39(8):647–51. doi:10.1007/s00595-009-3964-2 293 294 22. Bozzetti F, Bonfanti G, Castellani R, et al. Comparing reconstruction with 295 Roux-en-Y to a pouch following total gastrectomy. J Am Coll Surg. 1996;183(3):243-8. 296 297 23. He L, Zhao Y. Is Roux-en-Y or Billroth-II reconstruction the preferred choice for 298 gastric cancer patients undergoing distal gastrectomy when Billroth I reconstruction 299 is not applicable? A meta-analysis. Medicine. 2019;98(48):e17093. doi:10.1097/MD.0000000000017093 300 301 24. Park JY, Kim YJ. Uncut Roux-en-Y Reconstruction after Laparoscopic Distal 302 Gastrectomy Can Be a Favorable Method in Terms of Gastritis, Bile Reflux, and 303 Gastric Residue. J Gastric Cancer. 2014;14(4):229–37. 304 doi:10.5230/jgc.2014.14.4.229

25. Kim JH, Huh YJ, Park S, et al. Multicenter results of long-limb bypass 305 306 reconstruction after gastrectomy in patients with gastric cancer and type II diabetes. Asian J Surg. 2020;43(1):297-303. doi:10.1016/j.asjsur.2019.03.018 307 26. Wei ZW, Li JL, Wu Y, et al. Impact of pre-existing type-2 diabetes on patient 308 outcomes after radical resection for gastric cancer: a retrospective cohort study. Dig 309 310 Dis Sci. 2014;59(5):1017-24. doi:10.1007/s10620-013-2965-6 311 27. Yun L, Zhiwei J, Junsheng P, Xiaobin W, Cancan X, Jieshou L. Comparison of 312 Functional Outcomes between Functional Jejunal Interposition and Conventional 313 Roux-en-Y Esophagojejunostomy after Total Gastrectomy for Gastric Cancer. Dig 314 Surg. 2020;37(3):240-8. doi:10.1159/000501677 315 28. Kwon Y, Jung Kim H, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. A 316 systematic review and meta-analysis of the effect of Billroth reconstruction on type 317 2 diabetes: A new perspective on old surgical methods. Surg Obes Relat Dis. 318 2015;11(6):1386-95. doi:10.1016/j.soard.2015.01.001 319 29. An JY, Kim YM, Yun MA, Jeon BH, Noh SH. Improvement of type 2 diabetes 320 mellitus after gastric cancer surgery: short-term outcome analysis after gastrectomy. 321 World J Gastroenterol. 2013;19(48):9410-7. doi:10.3748/wjg.v19.i48.9410

322 30. Costa M, Trovão Lima A, Morais T, et al. Does Reconstruction Type After Gastric 323 Resection Matters for Type 2 Diabetes Improvement?. J Gastrointest Surg. 2020;24(6):1269-77. doi:10.1007/s11605-019-04255-4 324 325 31. Maksimaityte V, et al. Gastrectomy impact on the course of diabetes mellitus and 326 gut hormones. Surg Obes Relat Dis. 2021. doi:10.1016/j.soard.2020.08.031 327 32. Tseng CH, Lin JT, Ho HJ, et al. Gastric microbiota and predicted gene functions are 328 altered after subtotal gastrectomy in patients with gastric cancer. Sci Rep. 329 2016;6:20701. doi:10.1038/srep20701 330 33. Qi YF, Sun JN, Ren LF, et al. Intestinal Microbiota Is Altered in Patients with 331 Gastric Cancer from Shanxi Province, China. Dig Dis Sci. 2019;64(5):1193-203. doi:10.1007/s10620-018-5411-y 332 333 34. Lederer AK, Pisarski P, Kousoulas L, Fichtner-Feigl S, Hess C, Huber R. 334 Postoperative changes of the microbiome: are surgical complications related to the 335 gut flora? A systematic review. BMC Surg. 2017;17(1):125.

336

337

338

doi:10.1186/s12893-017-0325-8

19

35. Guyton K, Alverdy JC. The gut microbiota and gastrointestinal surgery. Nat Rev

Gastroenterol Hepatol. 2017;14(1):43–54. doi:10.1038/nrgastro.2016.139

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

36. Nomura E, Lee SW, Kawai M, et al. Functional outcomes by reconstruction technique following laparoscopic proximal gastrectomy for gastric cancer: double tract versus jejunal interposition. World J Surg Oncol. 2014;12:20. doi:10.1186/1477-7819-12-20 37. Nomura E, Kayano H, Lee SW, et al. Functional evaluations comparing the double-tract method and the jejunal interposition method following laparoscopic proximal gastrectomy for gastric cancer: an investigation including laparoscopic total gastrectomy. Surg Today. 2019;49(1):38-48. doi:10.1007/s00595-018-1699-7 38. Namikawa T, Munekage E, Munekage M, et al. Reconstruction with Jejunal Pouch after Gastrectomy for Gastric Cancer. Am Surg. 2016;82(6):510-7. 39. Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Impact of jejunal pouch interposition reconstruction after proximal gastrectomy for early gastric cancer on quality of life: short- and long-term consequences. Am J Surg. 2012;204(2):203-9. doi:10.1016/j.amjsurg.2011.09.035 40. Mochiki E, Kamimura H, Haga N, Asao T, Kuwano H. The technique of laparoscopically assisted total gastrectomy with jejunal interposition for early gastric cancer. Surg Endosc. 2002;16(3):540-4. doi:10.1007/s00464-001-8219-2

41. Takaori K, Nomura E, Mabuchi H, et al. A secure technique of intracorporeal

Roux-Y reconstruction after laparoscopic distal gastrectomy. Am J Surg.

2005;189(2):178-83. doi:10.1016/j.amjsurg.2004.09.008

## **Figure Legends**

356

357

358

359

360

362

363

364

365

Figure 1: Kaplan-Mayer curve of new onset of DM in RY and OT group

RY, Roux-en-Y; OT, other surgical techniques.

## **Tables**

**Table 1.** Demographics of the study population

|                               |   | RY          | ОТ           | P-value |
|-------------------------------|---|-------------|--------------|---------|
| Number of cases               |   | 489         | 226          |         |
| Age (SD)                      |   | 68.1 (10.6) | 70.0 (10.4)  | 0.031   |
| Male                          |   | 363 (74.2%) | 139 (61.5%)  |         |
| Height in cm (SD)             |   | 160.6 (8.6) | 157.9 (10.8) | 0.001   |
| Weight in kg (SD)             |   | 57.1 (11.1) | 56.9 (14.8)  | 0.865   |
| BMI in kg/m <sup>2</sup> (SD) |   | 22.1 (3.4)  | 24.6 (3.2)   | 0.246   |
| ASA score                     | 1 | 27 (5.5%)   | 21 (9.3%)    |         |

| 2 | 384 (78.5%) | 167 (73.9%) |
|---|-------------|-------------|
| 3 | 77 (15.7%)  | 34 (15.0%)  |
| 4 | 1 (0.2%)    | 4 (1.8%)    |

366 SD, standard deviation; BMI, body mass index; ASA, American Society of

Anesthesiology; RY, Roux-en-Y; OT, other surgical techniques.

367




Figure 1: Kaplan-Mayer curve of newly onset of DM in RY and OT group RY, Roux-en-Y; OT, other surgical techniques.